Cicely Saunders Institute, Dept of Palliative Care Policy and Rehabilitation, King's College London, London, UK.
University of Nottingham, Nottingham, UK.
Eur Respir J. 2020 Apr 23;55(4). doi: 10.1183/13993003.00815-2020. Print 2020 Apr.
Globally, the number of people affected by coronavirus disease 2019 (COVID-19) is rapidly increasing. In most (>80%), the illness is relatively mild and can be self-managed out of hospital. However, in about 20% the illness causes respiratory compromise severe enough to require hospital admission [1]. Patients with severe and critical disease need full active treatment. This may include oxygen for hypoxaemia and ventilatory support, along with optimal management of complications, super-imposed bacterial infection, and any underlying co-morbidities, chronic obstructive pulmonary disease, congestive heart failure. To date, no antiviral agent has shown to be effective in treating the disease [2].
全球范围内，感染 2019 冠状病毒病（COVID-19）的人数正在迅速增加。在大多数患者中（>80%），病情相对较轻，可以在院外自行管理。然而，约 20%的患者出现足以导致呼吸窘迫而需要住院的疾病[1]。重症和危重症患者需要全面积极的治疗。这可能包括针对低氧血症的氧疗和呼吸支持，以及对并发症、继发细菌感染和任何潜在合并症（如慢性阻塞性肺疾病、充血性心力衰竭）的最佳管理。迄今为止，尚无抗病毒药物被证明对治疗该疾病有效[2]。
